Want to see IL:INCR full AI Analyst Report?
INCR Stock Chart & Stats
514.20
>-0.01(-0.10%)
At close: 4:00 PM EST
514.20
>-0.01(-0.10%)
Day’s Range― - ―
52-Week Range225.30 - 605.00
Previous CloseN/A
Volume249.40K
Average Volume (3M)91.19K
Market Cap
₪177.80M
Enterprise Value283.64M
Total Cash (Recent Filing)₪46.67M
Total Debt (Recent Filing)₪183.01M
Price to Earnings (P/E)―
Beta0.66
Next Earnings
Aug 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.71
Shares Outstanding59,228,558
10 Day Avg. Volume173,192
30 Day Avg. Volume91,185
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)0.46
Price to Sales (P/S)0.68
P/FCF Ratio13.83
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Cash Generation RecoveryThe swing to positive operating cash flow (~16.8M) and free cash flow (~13.3M) in 2025 reflects improved working-capital and spending discipline. Durable cash generation reduces reliance on external financing, enables reinvestment or deleveraging, and supports operational resilience over the coming months.
Revenue ReboundAn 11.1% revenue rebound in 2025 after prior declines indicates restored demand or improved commercial execution. Sustained top-line recovery is a prerequisite for scalable margins and persistent cash conversion, providing a firmer base for structural profitability improvements over a 2–6 month horizon.
Improved LeverageLower debt-to-equity (~0.46 vs ~0.53) improves financial flexibility and reduces solvency pressure. Manageable leverage gives the company capacity to fund growth or absorb further short-term losses without immediate recourse to dilutive equity or costly borrowing, supporting stability over months.
Bears Say
Persistent UnprofitabilityContinued net losses through 2025 and a -13.2% margin show the company still cannot reliably convert revenue into profit. Prolonged unprofitability erodes equity, restricts reinvestment, and increases the likelihood of future external financing needs that could dilute returns or constrain strategy.
Margin CompressionSharp gross margin compression versus prior years suggests sustained pricing pressure, rising input costs, or adverse mix. Persistent margin deterioration limits the ability of revenue growth to improve operating profitability, making a durable turnaround dependent on structural margin repairs.
Cash-flow VolatilityThe 2025 cash-flow rebound follows large outflows in 2023–2024, indicating volatile cash generation. Such volatility raises financing and planning risk, weakening confidence that recent positive free cash flow is sustainable without persistent demand stability or structural cost reduction.
Intercure News
INCR FAQ
What was InterCure’s price range in the past 12 months?
InterCure lowest stock price was 225.30 and its highest was 605.00 in the past 12 months.
What is InterCure’s market cap?
InterCure’s market cap is ₪177.80M.
When is InterCure’s upcoming earnings report date?
InterCure’s upcoming earnings report date is Aug 17, 2026 which is in 33 days.
How were InterCure’s earnings last quarter?
InterCure released its earnings results on Feb 19, 2026. The company reported -62.8 earnings per share for the quarter, missing the consensus estimate of N/A by -62.8.
Is InterCure overvalued?
According to Wall Street analysts InterCure’s price is currently Overvalued.
Does InterCure pay dividends?
InterCure does not currently pay dividends.
What is InterCure’s EPS estimate?
InterCure’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does InterCure have?
InterCure has 59,228,558 shares outstanding.
What happened to InterCure’s price movement after its last earnings report?
InterCure reported an EPS of -62.8 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.696%.
Which hedge fund is a major shareholder of InterCure?
Currently, no hedge funds are holding shares in IL:INCR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
InterCure
InterCure Ltd., alongside its affiliated companies, is actively involved in the medical cannabis industry, operating both domestically in Israel and internationally. Their activities encompass the entire spectrum from research and cultivation to production, marketing, and distribution of medical cannabis products. The company's product line features dried cannabis flowers and an oil-based cannabis extract. Additionally, InterCure allocates investments to the biomedical sector. Established in 1994, the firm's main headquarters are situated in Herzliya, Israel.